Business
ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID
Approximately one in five American adults who had COVID-19 still experience symptoms of long COVID, a serious illness that can result in chronic conditions
About this update from Immunitybio, Inc.
[{"type":"text","content":"\n\nApproximately one in five American adults who had COVID-19 still experience symptoms of long COVID, a serious illness that can result in chronic conditions and disability1.2\n\n\n\nLong COVID remains a significant public health challenge with no currently available established treatments\n\n\n\nStudy explores ANKTIVA’s therapeutic potential as an IL-15 agonist in boosting NK cell responses against viral infections\n\n\n\n CULVER CITY, Calif.--(BUSINESS WIRE)--\nImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the opening of a new Phase 2 study to assess the BioShield™ platform, anchored by ANKTIVA® (nogapendekin alfa inbakicept-pmln), in patients with long COVID. An estimated one in five Americans with a previous COVID-19 infection has long COVID, which is comprised of a broad range of symptoms that can substantially impact a patient’s quality of life. Long COVID remains a significant public health challenge with no currently available established therapies.\n\n\nThe new study, called COVID-4.019-Long, further expands the company’s clinical research efforts to assess ANKTIVA’s potential beyond cancer or cancer-related diseases. Currently, ANKTIVA is being evaluated alone and with other agents in multiple studies for different forms of bladder cancer, non-small cell lung cancer, glioblastoma, non-Hodgkin lymphoma, Lynch syndrome, ovarian cancer and Human Papillomavirus (HPV) associated tumors. ANKTIVA is also being studied in Human Immunodeficiency Virus (HIV) and lymphopenia.\n\n\nThe primary objective of the exploratory, single-arm study (NCT07123727) is to evaluate the safety of ANKTIVA, injected under the skin (subcutaneously), in participants with long COVID. The secondary objective is to assess the effect of ANKTIVA on absolute lymphocyte count. Exploratory objectives include evaluation of ANKTIVA’s ability to improve post-COVID natural killer (NK) cell and CD8+ T cell counts, and assessment of the immunological function of NK cells and CD8+ T cells.\n\n\n“We are excited to study ANKTIVA for the treatment of long COVID, a substantial public health concern,” said Dr. Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. “Early in the pandemic, the common assumption was SARS-CoV-2 would prove to be a transient infection, as is the...